Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction
Autor: | Marilyn Marrari, Qingyong Xu, Joseph M. Pilewski, John F. McDyer, Eric P. Nolley, Pablo G. Sanchez, Massimo Mangiola, Adriana Zeevi, Cody A. Moore, Carlo J. Iasella, Christopher R. Ensor, Matthew R. Morrell |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
Pulmonary and Respiratory Medicine medicine.medical_specialty medicine.medical_treatment 030232 urology & nephrology Bronchiolitis obliterans Human leukocyte antigen 030230 surgery Gastroenterology Persistence (computer science) 03 medical and health sciences 0302 clinical medicine HLA Antigens Isoantibodies Internal medicine medicine Humans Transplantation Homologous Lung transplantation Bronchiolitis Obliterans Lung Retrospective Studies Transplantation biology business.industry Complement C1q Donor specific antibodies Graft Survival Middle Aged medicine.disease Tissue Donors Transplant Recipients medicine.anatomical_structure Chronic Disease Cohort biology.protein Female Surgery Primary Graft Dysfunction Antibody Cardiology and Cardiovascular Medicine business Follow-Up Studies Lung Transplantation |
Zdroj: | The Journal of Heart and Lung Transplantation. 39:1417-1425 |
ISSN: | 1053-2498 |
Popis: | Chronic lung allograft dysfunction (CLAD) is the major complication limiting long-term survival in lung transplant recipients (LTRs), with those developing donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) previously found to have increased risk for CLAD. However, as DSA responses vary in timing of development, specificity, breadth, persistence, and complement-binding capacity, we hypothesized that these characteristics would impact CLAD and survival outcomes.We retrospectively analyzed DSA characteristics and outcomes in a single-center cohort of 582 LTRs who had serum samples collected prospectively from 2010 to 2016. Luminex-based single antigen bead assays were performed to assess DSA.DSAs were detected in 247 LTRs (42%), of which 124 (21.3%) were de novo DSAs and 53 (9.1%) were complement-binding (C1q+). CLAD developed in 208 LTRs (35.7%) during the follow-up period, with 67.8% determined as bronchiolitis obliterans syndrome phenotype and 32.2% as restrictive allograft syndrome phenotype. We found a shorter time to CLAD in LTRs with persistent DSAs (p = 0.04) and HLA-DQ-specific DSAs (p = 0.03). LTRs who developed C1q+ DSAs had significantly shorter time to CLAD (p0.001), with 100% of C1q+ DSAs being persistent and no differences between CLAD phenotypes. CLAD-free survival was significantly reduced in LTRs who developed C1q+ DSAs (p = 0.001), HLA-DQ-specific DSAs (p = 0.03), and multiple DSAs (p = 0.02).Together, our findings demonstrate that DSA characteristics of persistence, HLA-DQ specificity, and C1q+ DSAs are associated with shorter time to CLAD. Additionally, C1q+, HLA-DQ-specific, and multiple DSAs are associated with decreased CLAD-free survival. These characteristics may improve DSA risk stratification for deleterious outcomes in LTRs. |
Databáze: | OpenAIRE |
Externí odkaz: |